Opus Genetics's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 78.81.
Opus Genetics's Days Inventory for the
three
months ended in Mar. 2026 was .
Opus Genetics's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, Opus Genetics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 78.81.
Opus Genetics (NAS:IRD) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Opus Genetics Cash Conversion Cycle Related Terms
Opus Genetics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRD vs IFRX, RGNX, LRMR: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Opus Genetics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Opus Genetics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a Cash Conversion Cycle of 78.81 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Opus Genetics and its competitors.
Is Opus Genetics' Cash Conversion Cycle too high?
Opus Genetics' current Cash Conversion Cycle is 78.81. The Biotechnology industry median Cash Conversion Cycle is 102.38. Opus Genetics' value of 78.81 is 23% below this industry median. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Cash Conversion Cycle compare to IFRX and RGNX?
Opus Genetics' Cash Conversion Cycle of 78.81 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.38. Opus Genetics' value of 78.81 is 23% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.38, based on 875 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current Cash Conversion Cycle of 78.81 is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Opus Genetics and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Cash Conversion Cycle is 78.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $3.67 — trading 890.5% above its estimated fair value. The current Cash Conversion Cycle is 78.81 and 23% below the Biotechnology industry median of 102.38. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Opus Genetics (IRD), the current Cash Conversion Cycle is 78.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $3.67 is trading 890.5% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
Cash Conversion Cycle: 78.81
GF Value™: $0.37 vs. price of $3.67 (890.5% above fair value)
Industry Position: 23% below the Biotechnology median
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
